Trilaciclib: A Novel Approach to Mitigate Chemotherapy-Induced Myelosuppression in Cancer Treatment

Abstract

Trilaciclib, a novel cyclin-dependent kinase 4/6 inhibitor, has demonstrated the ability to protect bone marrow from chemotherapy toxicity, improving patients' quality of life (QoL). This review describes the mechanism of action, efficacy, and toxicity profile of trilaciclib. Trilaciclib halts retinoblastoma protein phosphorylation during the early G1 phase, preventing the transition from the G1/S phase and inducing the cell cycle arrest in the G1 phase, which protects the hematopoietic cell lineages. Trilaciclib is indicated by the United States Food and Drug Administration and National Comprehensive Cancer Network to decrease the incidence of chemotherapy-induced myelosuppression in adult patients before a platinum/etoposide or topotecan containing regimen for extensive stage small cell lung cancer. Its ease of administration as an intravenous infusion, given before starting chemotherapy, and the favorable side effect profile make it a better-tolerated drug, improving patient QoL.

Keywords

trilaciclib - neutropenia - CDK 4/6 inhibitor - chemotherapy-induced myelosuppression

Note

No prior submissions.

The manuscript has been read and approved by all the authors, that the requirements for authorship as stated earlier in this document have been met, and that each author believes that the manuscript represents honest work.

Patient Consent

Not applicable.

Publikationsverlauf

Artikel online veröffentlicht:
30. April 2024

• References

• 1 Lyman GH. Febrile neutropenia: an ounce of prevention or a pound of cure. J Oncol Pract 2019; 15 (01) 27-29
• 2 Crawford J, Ozer H, Stoller R. et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991; 325 (03) 164-170
• 3 Crawford J, Dale DC, Kuderer NM. et al. Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw 2008; 6 (02) 109-118
• 4 Dinan MA, Hirsch BR, Lyman GH. Management of chemotherapy-induced neutropenia: measuring quality, cost, and value. J Natl Compr Canc Netw 2015; 13 (01) e1-e7
• 5 Kubista E, Glaspy J, Ann Holmes F. et al Bone Pain Associated with Once-Per-Cycle Pegfilgrastim Is Similar to Daily Filgrastim in Patients with Breast Cancer. Clin Breast Cancer 2003; 3 (06) 391-398
• 6 National Center for Biotechnology Information. PubChem Compound Summary for CID 68029831, Trilaciclib. Accessed March 24, 2023 at: https://pubchem.ncbi.nlm.nih.gov/compound/Trilaciclib
• 7 Weiss J, Goldschmidt J, Andric Z. et al. Effects of trilaciclib on chemotherapy-induced myelosuppression and patient-reported outcomes in patients with extensive-stage small cell lung cancer: pooled results from three phase II randomized, double-blind, placebo-controlled studies. Clin Lung Cancer 2021; 22 (05) 449-460
• 8 Dómine Gómez M, Csőszi T, Jaal J. et al. Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer. Int J Cancer 2021; 149 (07) 1463-1472
• 9 Daniel D, Kuchava V, Bondarenko I. et al. Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: a multicentre, randomised, double-blind, placebo-controlled phase II trial. Int J Cancer 2021; 148 (10) 2557-2570